Seeking Alpha

Amarin (AMRN) announces $100M in non-equity financing with an investment fund managed by...

Amarin (AMRN) announces $100M in non-equity financing with an investment fund managed by Pharmakon Advisors, and that it's continuing preparations to commercialize Vascepa capsules by hiring a sales force in the United States. Payments under this hybrid debt-like instrument are expected to be made over a 3.5-year period commencing in November 2013 and to continue through early 2017. Shares -21% AH.
From other sites
Comments (16)
  • arthurs1
    , contributor
    Comments (366) | Send Message
     
    This is why buying short term options is a fool's game. Long and intermediate term this is a positive. Of course it is arguable that investing, or a better term might be betting on biotech, is also a fool's game.
    6 Dec 2012, 04:29 PM Reply Like
  • rrobster
    , contributor
    Comments (149) | Send Message
     
    Best outcome here would be the FDA granting NCE status and a buyout of the company.
    6 Dec 2012, 05:35 PM Reply Like
  • Moosh
    , contributor
    Comments (126) | Send Message
     
    Wishful thinking, I am long Amrn, it looks like Amrn knows this will not happen, that's why AMRN raised money to go alone. Any feed back will be helpful.
    6 Dec 2012, 05:38 PM Reply Like
  • Moosh
    , contributor
    Comments (126) | Send Message
     
    I think we need to hang longer than what we were anticipating.
    6 Dec 2012, 05:40 PM Reply Like
  • rrobster
    , contributor
    Comments (149) | Send Message
     
    Agreed -and I am long too. I believe that this is part of Amarin's strategy to show potential suitors that they need to step in sooner rather than later, otherwise Amarin will go it alone and any potential suitors will have missed a huge opportunity.
    6 Dec 2012, 05:49 PM Reply Like
  • alan ljl
    , contributor
    Comments (260) | Send Message
     
    Sure, keep following "advice" from Seeking Alpha commenter's, author's et al. See where they lead you.
    6 Dec 2012, 06:40 PM Reply Like
  • rrobster
    , contributor
    Comments (149) | Send Message
     
    It's up to everyone to use this site (or not) as they see fit. As with anything related to investing, it's also up to them to do their own DD.
    6 Dec 2012, 07:08 PM Reply Like
  • Chris Lau
    , contributor
    Comments (2534) | Send Message
     
    $100mn non equity financing represents 5.6% of market cap - and it is non-dilution. The funds are being used for what investors already anticipated: to commercialize its main product. They have their own sales staff. This is good development, and the 20% drop will just shake off weak holders in this company.
    6 Dec 2012, 08:32 PM Reply Like
  • mitrado
    , contributor
    Comments (2019) | Send Message
     
    Maybe we'll see $7 a share... then big pharma will buy Amarin for $13 or $14 a share and all those who got in the 2 weeks prior to the approval will be left burning.

     

    I know this is cheap, but as the market keeps on proving, it can always get cheaper. I won't add any more shares above $8.
    7 Dec 2012, 05:31 AM Reply Like
  • CHECO
    , contributor
    Comments (2) | Send Message
     
    I am not a doctor but, as far as I know obesity goes hand to hand with cholesterol so, ARNA is on its wait to lunch its obesity drug and will definitely lower the need of Amarin's drug.
    7 Dec 2012, 03:02 PM Reply Like
  • OmegaWatcher
    , contributor
    Comments (11) | Send Message
     
    It's going to be a tough market to break through for Amarin; GSK's Lovaza already holds the market share for this segment of patients and Doctors are creatures of habit, I don't see them switching for something that hasn't shown any significant superiority in terms of efficacy.
    10 Dec 2012, 09:30 AM Reply Like
  • see punjabi
    , contributor
    Comments (363) | Send Message
     
    Omegawatcher,
    Use your brain, do some research and come back and explain how amrn drug is way superior compared to lovaza. Please don't make these kind of stupid statements without even knowing how these two therapies differ in terms of safety profile and efficacy.
    12 Dec 2012, 07:28 AM Reply Like
  • OmegaWatcher
    , contributor
    Comments (11) | Send Message
     
    See Punjabi, I have done my research.

     

    The only main difference between Vascepa and Lovaza is that Vascepa does not raise LDL-C. Most patients with high triglycerides would already be on a statin therapy anyways. The clinical efficacy of lowering of triglycerides is comparable to one another.

     

    Ever wonder why Vascepa hasn't done a head to head with Lovaza? I'm guessing it's because they don't see it being any more superior in triglyceride lowering.
    12 Dec 2012, 10:28 AM Reply Like
  • mitrado
    , contributor
    Comments (2019) | Send Message
     
    @see punjabi:

     

    Omegawatcher has no more than 7 comments, all of them raising doubts on Amarin's Vascepa. I wouldn't be surprised if this account belonged to Adam Feuerstein, the Criminal, or to any of his minions.

     

    Who exactly is Adam Feuerstein? http://bit.ly/zcz1QE
    After so much senseless defamation ... why is he not behind bars!? After all, that's where criminals belong: in jail.
    12 Dec 2012, 07:37 AM Reply Like
  • OmegaWatcher
    , contributor
    Comments (11) | Send Message
     
    Mitrado - I'm not linked to anyone, please do not assume or link me to anyone without knowing my background.
    12 Dec 2012, 10:57 AM Reply Like
  • mitrado
    , contributor
    Comments (2019) | Send Message
     
    That's the problem, OmegaWatcher, you have just joined the site to comment on this thread! You have no background. Therefore, I'm free to assume whatever I want, based on your lack of background.
    12 Dec 2012, 11:35 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs